VIMOVO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vimovo, and what generic alternatives are available?
Vimovo is a drug marketed by Horizon and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-two patent family members in twenty-four countries.
The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
DrugPatentWatch® Generic Entry Outlook for Vimovo
There have been twenty-nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (esomeprazole magnesium; naproxen), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for VIMOVO
International Patents: | 52 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 11 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIMOVO |
Drug Sales Revenues: | Drug sales revenues for VIMOVO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIMOVO |
What excipients (inactive ingredients) are in VIMOVO? | VIMOVO excipients list |
DailyMed Link: | VIMOVO at DailyMed |



Recent Clinical Trials for VIMOVO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
EMS | Phase 3 |
Hanyang University Seoul Hospital | Phase 2 |
Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for VIMOVO
Paragraph IV (Patent) Challenges for VIMOVO
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIMOVO | Delayed-release Tablets | esomeprazole magnesium; naproxen | 375 mg/20 mg and 500 mg/20 mg | 022511 | 1 | 2010-11-05 |
US Patents and Regulatory Information for VIMOVO
VIMOVO is protected by nine US patents.
Patents protecting VIMOVO
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Pharmaceutical compositions for the coordinated delivery of NSAIDS
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Method for treating a patient at risk for developing an NSAID-associated ulcer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
Method for delivering a pharmaceutical composition to patient in need thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method for delivering a pharmaceutical composition to patient in need thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIMOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | See Plans and Pricing | See Plans and Pricing |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | See Plans and Pricing | See Plans and Pricing |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | See Plans and Pricing | See Plans and Pricing |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | See Plans and Pricing | See Plans and Pricing |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIMOVO
See the table below for patents covering VIMOVO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Czech Republic | 9600069 | See Plans and Pricing | |
Japan | 3635432 | See Plans and Pricing | |
Malaysia | 121192 | NEW COMPOUNDS. | See Plans and Pricing |
Hong Kong | 1028045 | See Plans and Pricing | |
Yugoslavia | 31494 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIMOVO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0984957 | 2012/048 | Ireland | See Plans and Pricing | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
0984957 | 430 | Finland | See Plans and Pricing | |
1411900 | 2011/016 | Ireland | See Plans and Pricing | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
1411900 | 1190013-1 | Sweden | See Plans and Pricing | PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105 |
0124495 | SPC/GB01/006 | United Kingdom | See Plans and Pricing | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |